Chronic Rhinosinusitis (CRS) is one of the most common long-term illnesses in the U.S. and affects nearly 30 million Americans annually.¹ Symptoms include inflammation, nasal congestion, reduced sense of smell and facial pain and often results in decreased productivity and sleep, missed work days and diminished quality of life.

Unfortunately, 52% of patients fail to respond to standard treatments of oral antibiotics and steroids, steroid nasal sprays, and nasal saline rinses and many are reluctant to undergo invasive surgery with high revision rates.²

Saline has been a staple in medicine for centuries, used for cleaning wounds, reducing inflammation, rehydration and more.

Today, saline is a first-line treatment for chronic sinusitis patients³ as it dilutes mucus to promote clearing of antigens and bacterial biofilm and promotes inflammatory mediators to improve mucociliary function⁴. However, most “bottom-up” saline delivery approaches don’t successfully reach and rinse the critical frontal, sphenoid and ethmoid sinus cavities. As 89% of CRS cases involve the ethmoid sinus, it’s crucial that treatment effectively targets this area for optimal relief and long-term disease management⁵.